Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04555902
Other study ID # 2020-0761
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2, 2020
Est. completion date October 5, 2021

Study information

Verified date November 2021
Source Geisinger Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this evaluation, 3 different versions of mailers promoting annual mammograms are being sent to women on the month of their 50th and 64th birthdays. The researchers hypothesize that the use of behavioral nudges in the mailers should lead to increased uptake in mammogram screening.


Description:

Mammogram screening for women, starting at age 50, can significantly reduce the risk of complications due to breast cancer. As part of an existing outreach campaign, the health system mails a postcard and small gift (pink socks) to women on the month of their 50th and 64th birthdays to promote annual mammogram screening. The researchers are evaluating two new versions of the mailers against a standard mailer to see which version leads to greater uptake in mammograms. The new mailers have content that applies behavioral nudge theory - specifically, loss frames and fear appeals - to encourage taking action. One of the two new versions does not include the small gift, to test whether its inclusion or exclusion has any effect on mammogram screening.


Recruitment information / eligibility

Status Completed
Enrollment 1342
Est. completion date October 5, 2021
Est. primary completion date October 5, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years to 64 Years
Eligibility Inclusion Criteria: - Female Geisinger Health Plan members turning 50 and 64 in that month - For the 2020 campaign, birthdays from June 2020 (as opposed to August 2020) will be included due to a temporary suspension of the outreach program due to the COVID-19 pandemic since June - For the pre-post examination of the 2019 campaign, all months in that year will be included Exclusion Criteria: - Members who are on the do not contact list at Geisinger Health Plan

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Postcard
The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.
Small Gift
Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.
Loss Frame and Fear Appeals
The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.

Locations

Country Name City State
United States Geisinger Danville Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Geisinger Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Mammogram Completion at 12 months (2019) Binary variable indicating whether a mammogram was completed to be used for exploratory pre-post comparisons 12 months from 2019 intervention start date
Other Primary Care Provider Visits at 12 months (2019) Number of visits to be used for exploratory pre-post comparisons (proxy for increased preventative health care) 12 months from 2019 intervention start date
Other Breast Cancer Diagnosis at 12 months (2019) Binary variable indicating whether the woman was diagnosed with breast cancer 12 months from 2019 intervention start date
Other Emergency Department Visits at 12 months (2019) Number of Emergency Department Visits (proxy for increased costly utilization of health system resources) 12 months from 2019 intervention start date
Primary Mammogram Completion at 6 months (2020) Binary variable indicating whether a mammogram was completed 6 months from intervention start date
Secondary Mammogram Completion at 12 months (2020) Binary variable indicating whether a mammogram was completed (a longer time frame allows for late responses) 12 months from intervention start date
Secondary Primary Care Provider Visits at 6 months (2020) Number of visits (proxy for increased preventative health care) 6 months from intervention start date
Secondary Primary Care Provider Visits at 12 months (2020) Number of visits (proxy for increased preventative health care) 12 months from intervention start date
Secondary Obstetrician-Gynecologist Visits at 6 months (2020) Number of visits (proxy for increased preventative health care) 6 months from intervention start date
Secondary Obstetrician-Gynecologist Visits at 12 months (2020) Number of visits (proxy for increased preventative health care) 12 months from intervention start date
Secondary Breast Cancer Diagnosis at 6 months (2020) Binary variable indicating whether the recipient was diagnosed with breast cancer 6 months from intervention start date
Secondary Breast Cancer Diagnosis at 12 months (2020) Binary variable indicating whether the recipient was diagnosed with breast cancer 12 months from intervention start date
Secondary Emergency Department Visits at 6 months (2020) Number of Emergency Department Visits (proxy for increased costly utilization of health system resources) 6 months from intervention start date
Secondary Emergency Department Visits at 12 months (2020) Number of Emergency Department Visits (proxy for increased costly utilization of health system resources) 12 months from intervention start date
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A